HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mari Wataya-Kaneda Selected Research

Tuberous Sclerosis (Bourneville's Disease)

4/2024Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex.
8/2023Tuberous Sclerosis Complex.
11/2022Sirolimus relieves seizures and neuropsychiatric symptoms via changes of microglial polarity in tuberous sclerosis complex model mice.
1/2022Abnormal White Matter Microstructure in the Limbic System Is Associated With Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders.
8/2020Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial.
2/2018Dysregulation of autophagy in melanocytes contributes to hypopigmented macules in tuberous sclerosis complex.
1/2018Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
1/2017Tuberous sclerosis complex: Recent advances in manifestations and therapy.
1/2017Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
1/2016Lymphangioleiomyomatosis and multifocal micronodular pneumocyte hyperplasia in Japanese patients with tuberous sclerosis complex.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mari Wataya-Kaneda Research Topics

Disease

17Tuberous Sclerosis (Bourneville's Disease)
04/2024 - 05/2008
5Angiofibroma
04/2024 - 03/2009
4Epilepsy (Aura)
11/2022 - 05/2008
4Neoplasms (Cancer)
11/2022 - 05/2008
3Vitiligo
08/2023 - 03/2012
3Inborn Genetic Diseases (Disease, Hereditary)
11/2022 - 08/2015
2Fabry Disease (Fabry's Disease)
12/2023 - 02/2008
2Neurocutaneous Syndromes (Phakomatoses)
12/2023 - 08/2023
2Hamartoma
08/2023 - 08/2015
2Neurofibroma
01/2023 - 11/2019
2Seizures (Absence Seizure)
11/2022 - 01/2013
2Hypopigmentation (Hypomelanosis)
02/2018 - 01/2018
2Intellectual Disability (Idiocy)
08/2015 - 05/2008
2Skin Diseases (Skin Disease)
08/2014 - 12/2010
1Angiokeratoma
12/2023
1Blue rubber bleb nevus syndrome
12/2023
1Vascular Malformations
12/2023
1Neurofibromatosis 1 (Neurofibromatosis Type I)
01/2023
1Squamous Cell Carcinoma of Head and Neck
08/2021
1T-Cell Lymphoma (Lymphoma, T Cell)
06/2021
1Dermatomyositis (Dermatopolymyositis)
06/2021
1Respiratory Insufficiency (Respiratory Failure)
10/2020
1Stevens-Johnson Syndrome (Lyell's Syndrome)
10/2020
1Contact Dermatitis (Eczema, Contact)
01/2020
1Drug Eruptions (Drug Eruption)
01/2020
1Pancreatitis
01/2018
1Melanoma (Melanoma, Malignant)
06/2017
1Lymphangioleiomyomatosis (Lymphangiomyomatosis)
01/2016
1Hyperplasia
01/2016
1Cysts
01/2016
1Autistic Disorder (Autism)
08/2015
1Metabolic Diseases (Metabolic Disease)
08/2015
1Disease Susceptibility (Diathesis)
04/2015
1Hemorrhage
10/2014
1Prurigo
08/2014
1Eczema
08/2014
1Atopic Dermatitis (Atopic Eczema)
08/2014
1Dermatitis
08/2014
1Perivascular Epithelioid Cell Neoplasms
01/2013
1Skin Manifestations
01/2013
1Hypersensitivity (Allergy)
12/2010
1Anhidrotic Ectodermal Dysplasia 1
04/2009
1Hypohidrosis
04/2009
1Hypotrichosis
04/2009
1Anodontia (Hypodontia)
04/2009

Drug/Important Bio-Agent (IBA)

14trans-sodium crocetinate (crocetin)IBA
04/2024 - 05/2008
12Sirolimus (Rapamycin)FDA Link
04/2024 - 01/2012
7TOR Serine-Threonine KinasesIBA
12/2023 - 07/2015
3Mechanistic Target of Rapamycin Complex 1IBA
11/2022 - 08/2015
1EverolimusFDA Link
11/2022
1Prednisolone (Predate)FDA LinkGeneric
06/2021
1Azathioprine (Imuran)FDA LinkGeneric
06/2021
1Zonisamide (Zonegran)FDA LinkGeneric
10/2020
1apronalideIBA
01/2020
1LigandsIBA
11/2019
1RNA (Ribonucleic Acid)IBA
11/2019
1Messenger RNA (mRNA)IBA
11/2019
1IntegrinsIBA
11/2019
1Proto-Oncogene Proteins c-sis (Platelet Derived Growth Factor B)IBA
11/2019
1NivolumabIBA
06/2017
1lipoarabinomannan (LAM)IBA
01/2016
1Filaggrin ProteinsIBA
04/2015
1Melanins (Melanin)IBA
03/2015
1rhododendrolIBA
03/2015
1AntigensIBA
08/2014
1Ointments (Pastes)IBA
08/2014
1CytokinesIBA
03/2012
1Histamine Antagonists (Antihistamines)IBA
12/2010
1Hypnotics and Sedatives (Sedatives)IBA
12/2010
1EctodysplasinsIBA
04/2009
1Tuberous Sclerosis Complex 2 ProteinIBA
03/2009
1Tuberous Sclerosis Complex 1 ProteinIBA
03/2009
1RNA Splice SitesIBA
05/2008
1migalastatIBA
02/2008
1alpha-Galactosidase (Beano)IBA
02/2008
1EnzymesIBA
02/2008

Therapy/Procedure

8Therapeutics
12/2023 - 02/2008
1Radiotherapy
08/2021